临床肽组学:仪器、分析和应用进展。

IF 5 Q1 ENGINEERING, BIOMEDICAL
BME frontiers Pub Date : 2023-05-15 eCollection Date: 2023-01-01 DOI:10.34133/bmef.0019
Lin Li, Jing Wu, Christopher J Lyon, Li Jiang, Tony Y Hu
{"title":"临床肽组学:仪器、分析和应用进展。","authors":"Lin Li, Jing Wu, Christopher J Lyon, Li Jiang, Tony Y Hu","doi":"10.34133/bmef.0019","DOIUrl":null,"url":null,"abstract":"<p><p>Extensive effort has been devoted to the discovery, development, and validation of biomarkers for early disease diagnosis and prognosis as well as rapid evaluation of the response to therapeutic interventions. Genomic and transcriptomic profiling are well-established means to identify disease-associated biomarkers. However, analysis of disease-associated peptidomes can also identify novel peptide biomarkers or signatures that provide sensitive and specific diagnostic and prognostic information for specific malignant, chronic, and infectious diseases. Growing evidence also suggests that peptidomic changes in liquid biopsies may more effectively detect changes in disease pathophysiology than other molecular methods. Knowledge gained from peptide-based diagnostic, therapeutic, and imaging approaches has led to promising new theranostic applications that can increase their bioavailability in target tissues at reduced doses to decrease side effects and improve treatment responses. However, despite major advances, multiple factors can still affect the utility of peptidomic data. This review summarizes several remaining challenges that affect peptide biomarker discovery and their use as diagnostics, with a focus on technological advances that can improve the detection, identification, and monitoring of peptide biomarkers for personalized medicine.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"4 ","pages":"0019"},"PeriodicalIF":5.0000,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521655/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications.\",\"authors\":\"Lin Li, Jing Wu, Christopher J Lyon, Li Jiang, Tony Y Hu\",\"doi\":\"10.34133/bmef.0019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Extensive effort has been devoted to the discovery, development, and validation of biomarkers for early disease diagnosis and prognosis as well as rapid evaluation of the response to therapeutic interventions. Genomic and transcriptomic profiling are well-established means to identify disease-associated biomarkers. However, analysis of disease-associated peptidomes can also identify novel peptide biomarkers or signatures that provide sensitive and specific diagnostic and prognostic information for specific malignant, chronic, and infectious diseases. Growing evidence also suggests that peptidomic changes in liquid biopsies may more effectively detect changes in disease pathophysiology than other molecular methods. Knowledge gained from peptide-based diagnostic, therapeutic, and imaging approaches has led to promising new theranostic applications that can increase their bioavailability in target tissues at reduced doses to decrease side effects and improve treatment responses. However, despite major advances, multiple factors can still affect the utility of peptidomic data. This review summarizes several remaining challenges that affect peptide biomarker discovery and their use as diagnostics, with a focus on technological advances that can improve the detection, identification, and monitoring of peptide biomarkers for personalized medicine.</p>\",\"PeriodicalId\":72430,\"journal\":{\"name\":\"BME frontiers\",\"volume\":\"4 \",\"pages\":\"0019\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2023-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521655/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BME frontiers\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34133/bmef.0019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BME frontiers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34133/bmef.0019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

摘要

广泛致力于发现、开发和验证用于早期疾病诊断和预后的生物标志物,以及快速评估对治疗干预的反应。基因组和转录组分析是鉴定疾病相关生物标志物的公认方法。然而,对疾病相关肽体的分析也可以鉴定新的肽生物标志物或特征,这些生物标志物和特征为特定的恶性、慢性和传染性疾病提供敏感和特异的诊断和预后信息。越来越多的证据还表明,液体活检中的肽组变化可能比其他分子方法更有效地检测疾病病理生理学的变化。从基于肽的诊断、治疗和成像方法中获得的知识带来了有前景的新的治疗应用,可以在减少剂量的情况下提高其在靶组织中的生物利用度,以减少副作用并改善治疗反应。然而,尽管取得了重大进展,但多种因素仍然会影响肽组数据的效用。这篇综述总结了影响肽生物标志物发现及其诊断用途的几个剩余挑战,重点是可以改进个性化医学肽生物标志的检测、鉴定和监测的技术进步。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications.

Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications.

Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications.

Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications.

Extensive effort has been devoted to the discovery, development, and validation of biomarkers for early disease diagnosis and prognosis as well as rapid evaluation of the response to therapeutic interventions. Genomic and transcriptomic profiling are well-established means to identify disease-associated biomarkers. However, analysis of disease-associated peptidomes can also identify novel peptide biomarkers or signatures that provide sensitive and specific diagnostic and prognostic information for specific malignant, chronic, and infectious diseases. Growing evidence also suggests that peptidomic changes in liquid biopsies may more effectively detect changes in disease pathophysiology than other molecular methods. Knowledge gained from peptide-based diagnostic, therapeutic, and imaging approaches has led to promising new theranostic applications that can increase their bioavailability in target tissues at reduced doses to decrease side effects and improve treatment responses. However, despite major advances, multiple factors can still affect the utility of peptidomic data. This review summarizes several remaining challenges that affect peptide biomarker discovery and their use as diagnostics, with a focus on technological advances that can improve the detection, identification, and monitoring of peptide biomarkers for personalized medicine.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.10
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信